Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 7684 results

  1. Intermittent urethral catheters for urinary management in adults : Late Stage Assessment

    In development [GID-HTE10049] Expected publication date: TBC

    Health technology evaluations
    In development

  2. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development [GID-TA10981] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  3. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

    In development [GID-TA11571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  4. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development [GID-TA11140] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  5. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development [GID-TA11554] Expected publication date: 12 November 2025

    Technology appraisal guidance
    In development

  6. BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    Awaiting development [GID-TA11552] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development [GID-TA11023] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  8. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  9. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312

    Awaiting development [GID-TA11329] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    In development [GID-TA10893] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Efgartigimod for treating generalised myasthenia gravis [ID4003]

    In development [GID-TA10986] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

    In development [GID-TA10948] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

    Awaiting development [GID-TA10682] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development